Morepen Laboratories 2026: Stay on ₹117.94cr GST SCN

The legal relief that changed the immediate risk

Morepen Laboratories Limited has secured a stay from the Himachal Pradesh High Court on a GST show-cause notice involving ₹117.94 crore. The order dated January 6, 2026 temporarily halts the operation of the notice, offering the company protection from enforcement while the matter remains under judicial review. The company said the stay ensures no immediate impact on financial operations or business activities. The dispute relates to refund claims and the way accumulated input tax credit was claimed on zero-rated supplies. For investors, the stay does not end the case, but it reduces the near-term uncertainty around cash outflows linked to the notice.

What the GST show-cause notice alleges

The show-cause notice was issued by the Central GST and Central Excise Commissionerate, Shimla, dated December 2, 2025. Authorities alleged that Morepen Laboratories made excess GST refund claims. The notice cited provisions under Section 54 of the CGST Act, 2017 read with Rule 89 of the CGST Rules, 2017. The company has stated that it denies wrongdoing. It also indicated it would submit supporting documents and seek legal advice as the process continues. The notice covered the period FY 2020 to FY 2024, according to the information disclosed.

Court order, dates, and how the matter moved

Morepen filed a writ petition before the High Court of Himachal Pradesh at Shimla challenging the notice. The court reviewed the petition and granted a stay on the operation of the show-cause notice on January 6, 2026. The company stated it received the order on January 8, 2026 at 2:55 p.m. The stay effectively prevents immediate coercive action linked to the disputed demand during the pendency of proceedings. In separate references, the demand is also described as ₹118.00 crore or ₹1.18 billion, which aligns with the same approximate amount.

Company’s assessment: “no impact” on operations

In its statement, Morepen said the stay order results in no financial or operational impact. It specifically pointed to continuity in financial operations, business activities, and operational functioning. This is important because a live tax demand can create pressure on working capital and banking arrangements even before final adjudication. The stay, by design, reduces immediate enforcement risk rather than settling the underlying interpretation dispute. The next steps depend on the progress of the legal proceedings and submissions by the company.

Market reaction on the day

The stock reflected the broader sentiment around the development but still closed lower on the trading day referenced. Morepen Laboratories closed at ₹40.32, down ₹1.20 or 2.89% from the previous session. The move suggests that while the stay provides short-term relief, the overhang of a large indirect tax dispute can still weigh on sentiment. Market participants typically track whether such matters escalate into cash payments, penalties, or prolonged litigation. The company’s statement emphasised stability, but the market pricing showed caution.

What the dispute means in balance-sheet terms

The disputed amount was disclosed as 6.63% of the company’s total assets for FY 2025. That ratio helps investors gauge materiality beyond the headline figure. A tax dispute of this scale can influence perception around governance and compliance even when the company contests the claim. The stay reduces the chance of sudden financial disruption but does not remove the need for eventual resolution. The legal framing also indicates the case turns on the method used to claim refunds of accumulated input tax credit on zero-rated supplies.

Business snapshot and financial context

Morepen Laboratories is a pharmaceutical manufacturer with presence across APIs, home diagnostics, and OTC healthcare products. The company is known for the anti-allergy drug Loratadine and has domestic prominence in blood glucose monitors and blood pressure monitors. It is headquartered and manufactures out of Baddi, Himachal Pradesh, and operates 10 plants. The company, established in 1984, is listed on NSE and BSE (NSE: MOREPENLAB, BSE: 500288). It reported revenue of ₹1,681 crore and profit of ₹66 crore for FY26, and Q1 FY27 revenue of ₹541 crore.

Other notable corporate developments mentioned

Separately, Morepen Laboratories has announced a ₹825 crore CDMO deal with a global pharmaceutical major, described as an entry into the contract manufacturing segment. The company also disclosed that Dr. Morepen Limited ceased to be a subsidiary effective July 31, 2025 after Morepen Laboratories’ shareholding reduced to 19.96% from 80%. Another reported item in the dataset refers to Q3FY26 consolidated net profit of ₹2,750.93 crore and total income of ₹48,796.66 crore. These figures are presented as reported alongside other company disclosures in the provided information.

Key facts table

Market impact

The immediate market impact of the High Court stay is mainly risk containment rather than earnings expansion. A stay can reduce near-term concerns around cash outflows, bank covenants, and operational disruptions that sometimes follow large tax demands. However, the dispute remains open, and investors will likely watch for the company’s submissions, future hearings, and any change in the status of the stay. The report also flagged subdued profitability due to API margin compression, which adds a separate operational variable alongside the legal issue. Taken together, the event is relevant because it touches both compliance risk and the operating environment for pharmaceutical manufacturers.

Analysis: why the stay matters for investors

For a listed company, a court stay on a ₹117.94 crore GST show-cause notice is significant because it pauses enforcement while legal arguments are tested. It allows management to run the business without the immediate burden of a contested liability. The disclosure that the amount equals 6.63% of FY 2025 assets signals the dispute is material enough to track, even if the company contests it. The development also highlights how refund mechanisms for zero-rated supplies can become areas of scrutiny under GST, especially when large input tax credits accumulate.

Conclusion

Morepen Laboratories’ High Court stay on the ₹117.94 crore GST show-cause notice provides near-term legal protection and, as per the company, no immediate financial or operational impact. The underlying refund dispute remains active and will proceed through further legal and documentation stages. Investors are likely to monitor court timelines, any subsequent orders, and company disclosures on the matter. Future updates may also be shaped by operating factors such as API margin trends and progress on initiatives like the ₹825 crore CDMO deal.